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Pulmonary arterial hypertension (PAH) is a devastating, life-limiting disease driven by
small vessel vascular remodeling leading to a rise in pulmonary vascular resistance
(PVR). Patients present with a range of symptoms including shortness of breath,
exercise intolerance, palpitations or syncope. Symptoms may be related to vascular
disease progression or arrhythmia secondary to the adaptation of the right heart to
pressure overload. Arrhythmic burden is high in patients with left heart disease and
guideline-based treatment of arrhythmias improves quality of life and prognosis. In
PAH the incidence and prevalence of arrhythmias is less well-defined and there are no
PAH-specific guidelines for arrhythmia management. We undertook a literature search
identifying 13 relevant papers; detection of arrhythmias was acquired from 12-lead
electrocardiogram (ECG) or Holter monitors. In all forms of pulmonary hypertension
(PH) the prevalence of supraventricular arrhythmias (SVA) was 26–31%, ventricular
arrhythmias (VA) 24% and a 5-year incidence of SVA ∼13.2–25.1%. Prevalence and
incidence of arrhythmias in PAH is less clear due to limited study numbers and
the heterogenous nature of the patient population studied. For arrhythmia treatment,
only single-arm studies of therapeutic strategies were reported using antiarrhythmic
drugs (AAD), direct current cardioversion (DCCV) and ablation. Periods between
ECG or Holter have not been investigated, highlighting the possibility that significant
arrhythmias may be undetected. Advances in monitoring allow long-term surveillance
via implanted/non-invasive monitors. Use of such technologies may provide an accurate
estimate of incidence and prevalence of arrhythmias in patients with PAH, further defining
relationships to adverse outcomes, and therapeutic options.
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INTRODUCTION
The recent World Symposium classifies pulmonary hypertension
into five groups based on underlying cause (1). Group one
incorporates pulmonary arterial hypertension including familial
and idiopathic causes; group two is secondary to left sided
heart disease; group three to lung disease and hypoxia;
group four is secondary to chronic thromboembolic disease
(CTEPH) and group five includes miscellaneous causes including
sarcoidosis and hematological disease (1). Increased right
ventricular pressure and volume overload of the right heart
leads to structural changes that impair left ventricular filling
(2) and function which may predispose to the development
of arrhythmias. In this review we will discuss the prevalence
and incidence of arrhythmia in PAH and the potential
treatment options.
CARDIAC ARRHYTHMIAS:
CLASSIFICATION AND MECHANISM
Cardiac arrhythmias are caused by either disruption of the
cardiac action potential or structural/functional changes to
the heart that result in abnormalities of electrical conduction.
Classification is made based on heart rate (bradycardic
or tachycardic) and sub-divided based on site of origin
(supraventricular or ventricular arrhythmia). In the left and
right atrium, dilatation and stretch results in structural, and
ion channel adaptations resulting in an increased development
of SVA’s including atrial fibrillation (AF) and atrial flutter (see
Figures 1A,B). Subsequent loss of atrial contraction leads to
underfilling of the ventricle and reduction in cardiac output
(CO). VA’s can be precipitated by a dilated, dysfunctional
ventricle, or altered ventricular substrate in the form of scar (3),
giving rise to pro-arrhythmicmyocardium (see Figures 2A,B). In
left sided heart failure there is an increased risk of arrhythmia,
which when present often exacerbates left ventricular failure (3,
4). Impaired left ventricular function results in reduced CO due
to inadequate filling and contraction leading to compensatory
hypertrophy and dilatation of the left ventricle. These changes
increase sarcomere length and alter sensitivity to calcium leading
to more forceful ventricular contraction (5), the resultant ion
channel remodeling (6) can make myocardium pro-arrhythmic
(3). Bradyarrhythmia presents often secondary to changes in
heart structure, nodal fibrosis, or rate-limiting medication used
to treat heart failure.
Current guidelines for the treatment of arrhythmia specifically
relate to patients with left sided heart disease (4–9). Management
strategies include AAD’s that alter the action of specific
ion channels to stabilize myocardium; anticoagulation to
reduce stroke risk in AF (6); synchronized DCCV to revert
to normal sinus rhythm (NSR); electrophysiology studies
(EPS); and/or ablation to identify abnormal heart rhythms
using intracardiac catheters and ablation to disrupt abnormal
conduction pathways and finally permanent pacemakers or
internal defibrillator devices (7, 10). Guidance for the treatment
of arrhythmias in patients with PAH is lacking despite the
potential harmful/unknown effects of AAD’s and or therapies in
this cohort (7).
Arrhythmias in PAH
Patients with PAH often describe palpitations and/or syncope.
The incidence and prevalence of cardiac arrhythmias in PAH
is not well-described, however a number of recent studies
describe a significant arrhythmic burden in all forms of PH,
and a relationship to clinical outcome. These studies are
based on “snapshots” in time using 12 lead ECGs or short-
term Holter monitors. We undertook a literature-based review
searching PubMed with the search terms “pulmonary arterial
hypertension, supraventricular, and ventricular arrhythmias,
atrial fibrillation/flutter, ventricular tachycardia, and mode of
death,” 13 relevant papers were reviewed as well as PAH registry
data. A review of the REVEAL PAH registry data demonstrated a
relationship between increased heart rate and adverse outcomes
(11, 12) and during follow up, Burger et al. found 5.1% of patients
were admitted secondary to an arrhythmia, however further
details were not provided (13).
Supraventricular Arrhythmias
Prevalence
In a multi-center, observational study (14), patients with
PAH/inoperable CTEPH attending routine outpatients had their
notes reviewed retrospectively for evidence of AF or atrial
flutter. 297 patients were identified as fulfilling criteria (PAH
266/CTEPH 31) with 90% on PAH specific medication. An
ECG diagnosis of AF or atrial flutter was noted in 79 (26.5%),
approximately 50% of those were deemed to be paroxysmal in
nature. Patients with AF were as a group, of increased age, male
gender with a higher systolic blood pressure (BP), a reduced
left ventricular ejection fraction (LVEF), and had a higher rate
of chronic obstructive lung disease (COPD). At right heart
catheterization (RHC), the AF group had a higher pulmonary
capillary wedge pressure (PCWP), and lower pulmonary vascular
resistance, potentially suggesting a more elderly population with
a greater burden of co-morbid condition. There was no difference
found in mean pulmonary artery pressure (PAP) or CO. Results
suggest that a diagnosis of permanent or paroxysmal AF/atrial
flutter in PAH confers an increased mortality. The use of 12-
lead ECGs alone and the unbalanced co-morbidities of patients
with and without AF/atrial flutter masked the true burden of
arrhythmias in patients with PAH (14).
Rottlaender et al. (15), investigated patients with all forms of
PH who developed SVA in a retrospective study of 225 patients.
Thirty one percentage of patients recruited were found to have
AF (41% paroxysmal) and it was apparent that AF was more
likely if secondary to PH-left heart disease and less common
in CTEPH. All patients identified as having AF deteriorated
clinically at the time of arrhythmia. The true prevalence of
SVA was again difficult to determine due to the inclusion of
all types of PH. In contrast Ruiz-Cano et al. retrospectively
reviewed 282 patients with PAH. In total 28 SVA episodes were
detected: AF 12 patients (42.8%); atrial flutter 12 (42.8%); other
SVA 4 (14.2%), 82% of SVA episodes resulted in symptoms
and clinical deterioration / worsening right heart failure (RHF).
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FIGURE 1 | (A) An ECG of atrial fibrillation. An example of an ECG taken from a patient with atrial fibrillation showing uncoordinated atrial activity resulting in an
irregular ventricular rate. (B) An ECG of atrial flutter. An example of an ECG taken from a patient with atrial flutter. It is characterized by rapid, regular atrial
depolarizations (typically, but not always at a rate of 300 bpm) resulting in a ventricular rate of 150 bpm.
Time from PAH diagnosis to SVA was approximately 60 months
and time from SVA diagnosis to death/transplant was 17.8
months suggesting increased morbidity and mortality with the
development of SVA.
Incidence
A number of studies investigated incidence through
prospective/retrospective cohort studies (summarized in
Table 1), with 6-year incidence of SVA in PAH approximately
15.8% and in all forms of PH a 5-year incidence of between 13.2
and 25.1% (17–21). In a retrospective, cohort study, Cannillo
et al. examined patients with PAH, lung disease-associated PH,
and CTEPH who had NSR at baseline on a 12-lead ECG, patients
with previous SVA diagnosis were excluded (18). Retrospective
analysis of ECG’s was undertaken during follow-up, if admitted
or if they developed palpitations. Holter monitors were only
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FIGURE 2 | (A) An ECG of ventricular tachycardia. An example of an ECG from a patient with sustained monomorphic ventricular tachycardia. It is characterized by
regular, broad QRS complexes of similar morphology often over 100 bpm. (B) An ECG of Ventricular fibrillation. An example of an ECG from a patient with ventricular
fibrillation. It is characterized by rapid, erratic ventricular activity as the heart fibrillates rather than pumps effectively. This rhythm quickly degenerates into cardiac arrest.
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fitted in patients reporting palpitations, not as a screen for
asymptomatic SVA’s. 77 patients met criteria, 17 patients
(22%) were newly diagnosed with SVA during the follow-up
period (35 months). Patients were found to have persistent
AF in 8 patients (47%), permanent AF 3 patients (17%),
paroxysmal SVA 3 patients (17%), atrial ectopic tachycardia
2 patients (12%), right atrial flutter 2 patients (12%) and
paroxysmal AF (PAF) in 1 patient (6%), other SVA 1 patient
(6%). Diagnosis of SVA’s occurred on average 15.1 months after
PH diagnosis and was associated with worsening parameters
(World health organization (WHO)-functional class/6-min walk
test (6MWT)/brain natriuretic protein (BNP), and increased
mortality. This suggests SVA to be a manifestation of more
severe PAH [as per Tongers (21) and Ruiz-Cano (16)]. Severe
PAH resulted in more hospital admissions and closer monitoring
by default, potentially introducing detection bias of SVA in these
patients. Consistent with these findings, Mercurio et al. (17)
again looked at PAH only and specifically idiopathic PAH and
systemic sclerosis-associated pulmonary hypertension (SSc-PH).
A prospective, single center study recruited 317 patients in total
(116 idiopathic PAH) and of these 42 developed SVA. In keeping
with Smith et al. (14) these patients had higher baseline PCWP
and in this case right atrial pressure (RAP). In 90.1% cases the
onset of SVA resulted in clinical worsening and RHF. A 5-year
incidence of SVA in idiopathic PAH and SSc-PAH was found to
be 13.2%, lower than previously documented by Olsson et al. in a
similar PH group (20). Olsson et al. described a 5-year incidence
of 25.1% of SVA in PAH and inoperable CTEPH. Patients again
had NSR at baseline and diagnosis of arrhythmia was based on
12-lead ECG’s only. Forty-Eight patients (20%) had at least one
episode of SVA. They also showed patients with persistent AF
to have a worse prognosis than those with PAF or NSR (20).
This followed on from a previous study by Tongers et al. (21),
that retrospectively recruited 231 patients under follow-up for
PAH and inoperable CTEPH. Thirty-one episodes of SVA were
noted on 12-lead ECG in 27 patients (Atrial flutter 15, AF 13,
and other SVA 3). Episodes were again associated with marked
clinical deterioration and RHF (84% SVA episodes), improving
if NSR was restored. Interestingly this study appears to show
an increased mortality in AF patients where NSR could not be
restored. All 15 patients with atrial flutter had NSR, restored with
medication (1), DCCV (6), overdrive pacing (15) or ablation (5),
with one death during follow-up. In the AF group only 2 patients
had NSR restored by DCCV. NSR in the remaining 9 was not
achieved despite multiple medications and DCCV, with 8 deaths
during follow-up. This suggests an increased mortality in AF and
PAH if NSR is not achieved. It would also appear that treatment
measures in the AF group were less aggressive (ablation was
not attempted) but the study was from 2007 so potentially now
outdated as ablation is more common place today.
In patients with idiopathic PAH on disease specific therapies
Wen et al. (19) undertook a prospective, cohort study with 280
patients recruited specifically with NSR at baseline. Forty patients
developed SVA at least once during follow-up, 5-year incidence
was calculated as 15.8%, potentially a more realistic reflection in
PAH alone. Patients as with previous studies did not tolerate SVA
and restoration of NSR correlated with clinical recovery. Studies
again only diagnosed SVA on 12-lead ECG, potentially failing to
diagnose asymptomatic SVA.
Treatment
AAD’s, overdrive pacing, DCCV, and radiofrequency ablation
are all guideline based therapies for SVA (6, 7), (although not
PAH-specific). Existing data showed that rhythm control has
been the most popular first line strategy and restoration of
NSR demonstrated clinical improvement. Cannillo et al. (18)
attempted rhythm control in 76% of patients diagnosed with
SVA, NSR was restored in 11 (65%) cases but there was a high
recurrence rate (∼80%). Olsson et al. (20) diagnosed patients
with SVA on 12-lead ECG and largely from patients presenting
with deterioration of PAH/RHF symptoms rather than symptoms
of arrhythmia [as per Cannillo et al. (18)]. Those with atrial flutter
received ablation earlier with the concurrent use of AAD’s with or
without synchronized DCCV. For stable AF 10–14 days of oral
amiodarone was prescribed pre DCCV and continued thereafter.
If there were signs of RHF, amiodarone was given intravenously,
and DCCV was performed. NSR was restored in 21/24 patients
with atrial flutter and 16/24 patients with AF, resulting in clinical
improvement. As such this observational study demonstrates
that amiodarone was well-tolerated in PAH. Five-year survival
in PAH/inoperable CTEPH was 68% with a fall to 58% if
the patient developed a transient SVA and reduced further to
47% in permanent SVA. They also found that AF was more
resistant to treatment than atrial flutter (similar to non-PAH
disease). Consistent with these findings, Ruiz-Cano et al. (16)
found that after the first episode of SVA (despite restoration of
NSR/adequate rate control) 46.4% patients required an increase
in PAH-specific medications secondary to progressive RHF, an
interesting observation but not guideline directed. This data may
suggest that the onset of SVA can be a prelude to RHF and/or
clinical deterioration and that restoration of NSR or escalating
PAH-specific therapy should be considered. Zhang et al. (22)
specifically reviewed the efficacy and safety of electrophysiology
studies and ablation in SVA and PAH. A retrospective study
it reviewed 300 patients over 3 years [PAH 100 (observation)
and non-PAH 200 (control)] with PAF undergoing ablation for
the first time. All patients had a 24 h Holter monitor fitted
immediately post ablation and AAD’s were stopped 2 months
later. EPS and ablation were found to be safe and reasonably
effective in this cohort of patients. Bandorski et al. (23) agreed
and found that 12/14 patients (all PH types) with a diagnosis
of atrial flutter during EPS subsequently had successful ablation.
Zhang et al. (22) noted that 11.3% of patients had an early
recurrence PAF and 7.3% a late recurrence, with some correlation
between a higher RAP and the incidence of late PAF recurrence.
In conclusion, incidence of SVA in PH (including PAH) ranges
from 13.2 to 25.1% with a relationship to clinical worsening.
As such this may be an indicator for restoration of NSR or
alteration of PAH specific therapy. A range of therapeutic
strategies have been investigated, however conclusions on efficacy
are challenging to substantiate as the majority of studies were
single arm. Little evidence of harm was identified. As in left heart
disease NSR was easier to restore in atrial flutter vs. AF and all
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TABLE 1 | Summary of literature reviewing SVA in PH.
Reference Type of study Pathology Number of patients Demographics
in arrhythmia group
Prevalence/
incidence
Investigation Rhythm identified NSR restored? Treatment given Outcome
Smith et al. (14) Retrospective 4-year
study
PAH CTEPH PAH 266 CTEPH 31 F:M 53:14%
Age 61.8±14
MeanPAP 44±11
Prevalence 12-Lead ECG AF/atrial flutter
50% paroxysmal
31 patients 86% AAD’s
14% Not specified
Rottlaender et al. (15) Retrospective 4-year
study
All types of PH Total 225 F:M 36:64%
Age 71.2±1.1
MeanPAP 40.8±1.6
Prevalence 12 Lead ECG AF 41% paroxysmal Not discussed Not discussed Permanent AF = Clinical
deterioration.
Ruiz- Cano et al. (16) Retrospective, 4-year,
single center study
PAH Total 282 F:M 61:39%
Age 47.3±4.3
Prevalence Medical
notes/12-lead
ECG
AF/atrial flutter
/atrioventricular node
re-entry tachycardia
(AVNRT)
Attempted in all All underwent EPS +/−
ablation
Restoration of NSR =
clinical improvement
4 SVA recurrence
Mercurio et al. (17) Prospective, single
center study
Idiopathic PAH
PAH-SSc
116 IPAH
201 SSc-PH
F:M 71-29%
Age 59+-12.1
MeanPAP 47.3+-14.3
Incidence at 5
years 13.2%
AF/atrial flutter/atrial
tachycardia
Attempted in all 90.1% SVA = clinical
worsening/RHF.
Restoration of NSR =
clinical improvement
Cannillo et al.
(18)
Retrospective, single
center study? type of
PH experienced SVA
PAH
PH secondary to lung
disease
CTEPH (inoperable)
Total 77 F:M 55:45%
Mean age 63
MeanPAP 43
Incidence 12 Lead ECG
Holter
if symptomatic
AF/atrial flutter
4 paroxysmal (23%).
13 patients AAD’s/DCCV/ablation
SVA = worsening
prognostic parameters and
RHF.
NSR restored in 11 cases
Recurrent SVA in 9 patients
Li-Wen et al. (19) Prospective, cohort
6-year study
Idiopathic PAH (all
taking PH meds)
Total 280 F:M 72.5:27.5%
Age 39+-15
MeanPAP 64+-18
Incidence at 6
years (15.8%)
AF/atrial flutter /atrial
tachycardia
21 patients AAD’s/DCCV/ablation
SVA = clinical deterioration
NSR restored = clinical
improvement
6 x recurrence
Olsson et al. (20) Prospective 5-year,
single center study
PAH or CTEPH
(inoperable)
NSR at baseline, all
receiving PH meds
157 PAH
82 Inoperable CTEPH
F:M 65:35%
Age 58+-9
MeanPAP 52+-8
Incidence at 5
years (25.1%)
12-Lead ECG AF/atrial flutter 21/24 atrial flutter
16/24 AF
AAD’s/overdrive pacing
/DCCV/ablation
NSR = clinical improvement
Tongers et al. (21) Retrospective 6-year
study
PAH
CTEPH (inoperable)
Total 231 F:M 65:35%
Age 49+-13
MeanPAP 50+-10
Cumulative
incidence of
11.7% and annual
risk of 2.8%/
patient.
12 Lead ECG
AVNRT
diagnosed
on EPS
AF/atrial flutter /AVNRT
4 SVA recurrence
15/15 atrial flutter
2/13 AF
AAD’s/overdrive pacing
/DCCV/ablation
Restoration of NSR =
clinical improvement.
Increased mortality in
AF group
Zhang et al. (22) Retrospective, 3-year,
single center study
PAH
Non- PAH
PAF
PAH 100
Non-PAH 200
F:M 54.4:45.6%
Age 62.9 + 6.8
MeanPAP 31.9+-6.2
X Holter post
ablation + 24-h
Holter 3 monthly
11.3% early recurrence
of PAF
7.3% Late recurrence
of PAF
Attempted in all All patients underwent
radiofrequency ablation
AAD’s stopped 2 months
post ablation
Suggests raised PAP
increases chance of late
recurrence PAF.
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studies suggested that restoration of NSR resulted in improved
clinical outcomes.
Ventricular Arrhythmias
The impact of ventricular arrhythmias in patients with PH
is examined in a series of papers by Bandorski et al. An
initial retrospective, two-center study (23) analyzed data from
55 PH patients presenting with indications for EPS (14 with
group I PH). Fifteen had non-sustained ventricular tachycardia
(NSVT) on a Holter monitor, however the prognostic relevance
is unclear although likely to infer increased risk and extrapolation
of prevalence from such a study is challenging due to small
numbers and the large contribution of patients (23 in this
study) with left heart disease-associated PH. There were no
evidence suggesting EPS or ablation to be unsafe or ineffective in
PH patients.
In a larger study, Bandorski et al. (24) sought to determine
the incidence of VA in PH. Ninety two patients were
enrolled in total (54 Group I, 10 Group 3, 26 Group 4,
2 Group 5), all of whom were on PAH-specific medication
and in NSR at the time of enrolment. During 72-h Holter
monitoring, 17 patients (18.5%) had a detectable arrhythmia
[NSVT (12 patients), second degree atrioventricular block (1),
intermittent complete heart block (1), and atrial flutter (1)].
Although small and including patients with all PH types,
they undertook Holter monitoring and found arrhythmia in
asymptomatic patients highlighting the potential inaccuracy
of determining the incidence or prevalence of asymptomatic
arrhythmia from 12-lead ECG. It highlighted that the use of
Holter monitoring in this cohort was beneficial for arrhythmia
diagnosis and this may be a useful tool in PAH patients
also. To determine the prognostic significance of NSVT
Bandorski et al. (25) examined 78 patients with PAH or
inoperable CTEPH. Fifty-Five patients with PAH and 23 CTEPH
underwent a clinical review, bloods, Holter monitoring, 6 MWT,
echocardiography and RHC (25), of whom 12 had newly
detected NSVT.
Relatively little evidence exists defining the prevalence and
incidence of VA in PAH. Prevalence is estimated to be ∼27%
in all PH types with a considerable proportion of whom have
co-existing left heart disease. Longer studies utilizing Holter
monitoring rather than 12-lead ECG show higher rates of VA
suggesting a bias in methods. The most reliable incidence of
VA in all PH was ∼15–18.5% based on Holter monitoring (25)
suggesting a significant burden. Therapeutic options are unclear
with only single arm studies available.
Bradyarrhythmia’s
Limited data is available. Whilst determining the incidence of
VA in PH Bandorski et al. (24), identified that 4/17 patients
with newly diagnosed arrhythmias had intermittent heart block.
Two patients, despite not taking rate limiting medication,
progressed to complete heart block, and required pacemaker
implantation. Studies are small and the relationship to poor
outcome is uncertain.
Mode of Death
The predominant cause of death in patients with PAH is thought
to be RHF or sudden cardiac death (SCD) (26). Hoeper et al.
(27) undertook a retrospective, multi-center (17 referral centers
in Europe and the United States) looking at patients with
PAH who had developed cardiac arrest. 3130 patients with
PAH were treated over 3 years and 513 had circulatory arrest.
Cardiopulmonary resuscitation (CPR) was attempted in 132
(26%) but despite themajority occurring in a hospital setting only
8 patients (6%) survived to > 90 days. No apparent differences
were found preceding cardiac arrest accounting for why a patient
did or did not survive. It is difficult to fully assess cause of
death, this data showed that 54% of patients were admitted
with intercurrent illness; 49% died from progressive RHF; 18%
respiratory failure, and 8% from other causes. Seventeen percent
died from SCD and it is unclear as to whether this was secondary
to PAH progression or potentially treatable arrhythmia.
CONCLUSION
Present data suggest that patients with PH have increased risk
of arrhythmia, however accurate estimates of incidence and
prevalence in patients with PAH remain elusive. PAH is a rare
disease and as such patient numbers are often limited and
the studies undertaken have grouped patients with PAH with
other forms of related disease. As such, longitudinal studies
with defined enrolment criteria are required to determine
the arrhythmic burden of patients with PAH. The enrolment
of patients with pre-existing symptoms is a potential source
of bias exemplified by the increased rates of asymptomatic
SVA and VA (24) identified with prolonged monitoring.
Arrhythmias have been demonstrated to precede adverse
clinical events and it is therefore of clinical importance to
accurately define prevalence and incidence and examine
potential therapeutic options. Current evidence highlights
gaps in our knowledge as we only have “snapshots” of data
from a 12-Lead ECG or Holter monitoring. Advances in
technology now allow for long term monitoring of cardiac
rhythm and as such a prospective study with continuous
monitoring may further inform incidence, prevalence
and relationships to adverse outcomes, prior to studies of
therapeutic strategies.
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NOMENCLATURE
6MWT: 6-minute walk test
AAD: Antiarrhythmic drugs
AF: Atrial fibrillation
AVNRT: Atrioventricular node re-entry tachycardia
BP: Blood pressure
BNP: Brain natriuretic protein
CO: Cardiac output
COPD: Chronic obstructive pulmonary disease
CPR: Cardiopulmonary resuscitation
CTEPH: Chronic thromboembolic pulmonary hypertension
DCCV: Direct current cardioversion
ECG: Electrocardiogram
EPS: Electrophysiology study
LVEF: Left ventricular ejection fraction
NSR: Normal sinus rhythm
NSVT: Non-sustained ventricular tachycardia
PAF: Paroxysmal atrial fibrillation
PAH: Pulmonary arterial hypertension
PAP: Pulmonary arterial pressure
PCWP: Pulmonary capillary wedge pressure
PH: Pulmonary hypertension
PVR: Pulmonary vascular resistance
RAP: Right atrial pressure
RHC: Right heart catheter
RHF: Right heart failure
SCD: Sudden cardiac death
SSc-PH: Systemic sclerosis-associated pulmonary hypertension
SVA: Supraventricular arrhythmia
VA: Ventricular arrhythmia
WHO: World health organization
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